摘要
药物性肝损伤(drug-induced liver injury,DILI)是药物不良反应和药物撤市或限制使用的主要原因。生物标志物检测是临床前药物肝毒性评价和临床患者潜在肝损伤诊断的重要技术手段。随着组学技术的快速发展和肝损伤机制研究的不断深入,关于新型DILI生物标志物研究报道也越来越多。本文综述了近年来国内外DILI生物标志物研究的最新进展,以期为更好地评价药物潜在的肝毒性风险提供参考,为临床肝损伤诊断提供依据。
Drug-induced liver injury （DILl） is the main cause of adverse drug reactions, and drug withdrawal or restrictions. Biomarkers are important tools for evaluating preclinical drug hepatotoxicity and clinical diagnosis of potential liver injury in patients. In recent years, with the rapid development of omics technology and the development of mechanism research of of liver injury, there were more and more reports on new DILI biomarkers. In this paper, recent advances in the research of DILI biomarkers at home and abroad were reviewed, which could provide references for better evaluation of the potential risk of hepatotoxicity and clinical diagnosis of liver injury.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2018年第1期47-52,共6页
Chinese Journal of New Drugs
基金
国家“重大新药创制”科技重大专项资助项目(2015zX09501004m02,2015zx09501007-004)
关键词
药物性肝损伤
生物标志物
组学技术
肝损伤机制
drug-induced liver injury
biomarker
omics technology
mechanism of liver injury
